一分钟看懂
这是一项关于肺癌的III 期研究，登记的药物或干预包括zongertinib；pembrolizumab；cisplatin；carboplatin；pemetrexed，当前状态为研究进行中，已停止招募。登记地点显示中国北京、成都、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
zongertinib；pembrolizumab；cisplatin；carboplatin；pemetrexed · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记摘要未单独列出可展示的排除条件，请查看英文原文并向研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital of Chinese Academy of Medical Science · 北京
- Beijing Cancer Hospital · 北京
- West China Hospital, Sichuan University · 成都
- Fujian Cancer Hospital · 福州
- Guangdong Provincial People's Hospital · 广州
- The First Affiliated Hospital, Zhejiang University · 杭州
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine · 杭州
- Zhejiang Cancer Hospital · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Fudan University Shanghai Cancer Center · 上海
- Zhongshan Hospital Affiliated to Fudan University · 上海
- Taizhou Hospital of Zhejiang Province · 台州
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- Union Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
- First Affiliated Hospital of Xiamen University · 厦门
- Henan Cancer Hospital · 郑州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- Inclusion criteria:
- 1. Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
- Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
- 2. Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the ICF.
- 3. Histologically or cytologically confirmed diagnosis of an advanced and/or metastatic non-squamous Non-small cell lung cancer (NSCLC).
- 4. Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results.
- 5. An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status. If no archival tissue is available, this may be acceptable in exceptional cases after written agreement with the sponsor.
- 6. Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease and are not eligible for curative therapy.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06151574；登记信息更新于 2026-10-01；本站同步于 2026-10-08。